Disease Models & Mechanisms (Jun 2023)
Effectiveness of irinotecan plus trabectedin on a desmoplastic small round cell tumor patient-derived xenograft
- Valentina Zuco,
- Sandro Pasquali,
- Monica Tortoreto,
- Stefano Percio,
- Valentina Doldi,
- Marta Barisella,
- Paola Collini,
- Gian Paolo Dagrada,
- Silvia Brich,
- Patrizia Gasparini,
- Marco Fiore,
- Michela Casanova,
- Anna Maria Frezza,
- Alessandro Gronchi,
- Silvia Stacchiotti,
- Andrea Ferrari,
- Nadia Zaffaroni
Affiliations
- Valentina Zuco
- Molecular Pharmacology Unit, Department of Experimental Oncology, Fondazione IRCSS Istituto Nazionale dei Tumori, 20133 Milan, Italy
- Sandro Pasquali
- Molecular Pharmacology Unit, Department of Experimental Oncology, Fondazione IRCSS Istituto Nazionale dei Tumori, 20133 Milan, Italy
- Monica Tortoreto
- Molecular Pharmacology Unit, Department of Experimental Oncology, Fondazione IRCSS Istituto Nazionale dei Tumori, 20133 Milan, Italy
- Stefano Percio
- Molecular Pharmacology Unit, Department of Experimental Oncology, Fondazione IRCSS Istituto Nazionale dei Tumori, 20133 Milan, Italy
- Valentina Doldi
- Molecular Pharmacology Unit, Department of Experimental Oncology, Fondazione IRCSS Istituto Nazionale dei Tumori, 20133 Milan, Italy
- Marta Barisella
- Soft Tissue Tumor Pathology Unit, Department of Advanced Diagnostics, Fondazione IRCSS Istituto Nazionale dei Tumori, 20133 Milan, Italy
- Paola Collini
- Soft Tissue Tumor Pathology Unit, Department of Advanced Diagnostics, Fondazione IRCSS Istituto Nazionale dei Tumori, 20133 Milan, Italy
- Gian Paolo Dagrada
- Soft Tissue Tumor Pathology Unit, Department of Advanced Diagnostics, Fondazione IRCSS Istituto Nazionale dei Tumori, 20133 Milan, Italy
- Silvia Brich
- Soft Tissue Tumor Pathology Unit, Department of Advanced Diagnostics, Fondazione IRCSS Istituto Nazionale dei Tumori, 20133 Milan, Italy
- Patrizia Gasparini
- Epigenomics and biomarkers of solid tumors, Department of Experimental Oncology, Fondazione IRCSS Istituto Nazionale dei Tumori, 20133 Milan, Italy
- Marco Fiore
- Sarcoma Service, Department of Surgery, Fondazione IRCSS Istituto Nazionale dei Tumori, 20133 Milan, Italy
- Michela Casanova
- Pediatric Oncology Unit, Department of Cancer Medicine, Fondazione IRCSS Istituto Nazionale dei Tumori, 20133 Milan, Italy
- Anna Maria Frezza
- Medical Oncology Unit 2, Department of Cancer Medicine, Fondazione IRCSS Istituto Nazionale dei Tumori, 20133 Milan, Italy
- Alessandro Gronchi
- Sarcoma Service, Department of Surgery, Fondazione IRCSS Istituto Nazionale dei Tumori, 20133 Milan, Italy
- Silvia Stacchiotti
- Medical Oncology Unit 2, Department of Cancer Medicine, Fondazione IRCSS Istituto Nazionale dei Tumori, 20133 Milan, Italy
- Andrea Ferrari
- Pediatric Oncology Unit, Department of Cancer Medicine, Fondazione IRCSS Istituto Nazionale dei Tumori, 20133 Milan, Italy
- Nadia Zaffaroni
- Molecular Pharmacology Unit, Department of Experimental Oncology, Fondazione IRCSS Istituto Nazionale dei Tumori, 20133 Milan, Italy
- DOI
- https://doi.org/10.1242/dmm.049649
- Journal volume & issue
-
Vol. 16,
no. 6
Abstract
No abstracts available.Keywords
